CoChat
Sign Up
Cited by 151Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatmentsProtein Structure and Dynamics

The DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.

Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease

Open access
Tóth, Gergely, Gardai, Shyra J., Zago, Wagner, Bertoncini, Carlos W., Cremades, Nunilo, Roy, Susan L., Tambe, Mitali A., Rochet, Jean-Christophe, Galvagnion, Celine, Skibinski, Gaia, Finkbeiner, Steven, Bova, Michael, Regnstrom, Karin, Chiou, San-San, Johnston, Jennifer, Callaway, Kari, Anderson, John P., Jobling, Michael F., Buell, Alexander K., Yednock, Ted A., Knowles, Tuomas P. J., Vendruscolo, Michele, Christodoulou, John, Dobson, Christopher M., Schenk, Dale, McConlogue, Lisa·2014·PLoS ONE
DOI 10.1371/journal.pone.0087133PMC PMC3925190
Open this paper in CoChat — free accountOpen PDF

Abstract

The misfolding of intrinsically disordered proteins such as α-synuclein, tau and the Aβ peptide has been associated with many highly debilitating neurodegenerative syndromes including Parkinson's and Alzheimer's diseases. Therapeutic targeting of the monomeric state of such intrinsically disordered proteins by small molecules has, however, been a major challenge because of their heterogeneous conformational properties. We show here that a combination of computational and experimental techniques has led to the identification of a drug-like phenyl-sulfonamide compound (ELN484228), that targets α-synuclein, a key protein in Parkinson's disease. We found that this compound has substantial biological activity in cellular models of α-synuclein-mediated dysfunction, including rescue of α-synuclein-induced disruption of vesicle trafficking and dopaminergic neuronal loss and neurite retraction most likely by reducing the amount of α-synuclein targeted to sites of vesicle mobilization such as the synapse in neurons or the site of bead engulfment in microglial cells. These results indicate that targeting α-synuclein by small molecules represents a promising approach to the development of therapeutic treatments of Parkinson's disease and related conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0087133

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Fragment probe mapping identifies potential small-molecule binding pockets in monomeric αSyn. A. Structural properties of the 100 analyzed conformations from the NMR-derived ensemble structure of αSyn; correlation between the radius of gyration (Rg), solvent accessible surface area (SASA) and the number of non-bonded contacts. The gray circles represent the αSyn conformations, which were used for the fragment probe mapping calculations. B. 2D chemical structure of small molecules used as fragment probes in the fragment probe mapping calculations. C. 3D representation of the eight pockets identified within αSyn conformations filled with clusters of small molecules resulting from the fragment probe mapping calculations. Residues of αSyn are colored according to the amino acid sequence.
Figure 1 Fragment probe mapping identifies potential small-molecule binding pockets in monomeric αSyn. A. Structural properties of the 100 analyzed conformations from the NMR-derived ensemble structure of αSyn; correlation between the radius of gyration (Rg), solvent accessible surface area (SASA) and the number of non-bonded contacts. The gray circles represent the αSyn conformations, which were used for the fragment probe mapping calculations. B. 2D chemical structure of small molecules used as fragment probes in the fragment probe mapping calculations. C. 3D representation of the eight pockets identified within αSyn conformations filled with clusters of small molecules resulting from the fragment probe mapping calculations. Residues of αSyn are colored according to the amino acid sequence.CC BY · PubMed Central
Figure 2 ELN484228 provides protection in cellular models of αSyn-mediated dysfunction. A. ELN484228 alleviates αSyn-mediated impairment of vesicular dynamics. H4 neuroglioma cells over-expressing αSyn from a tetracycline inducible promoter were cultured for 24 hours in the absence or presence of 1 µg/ml tetracycline to induce αSyn and ELN484228 or control compound ELN484217 (compound number 38 in table S4 in Supporting Information text file S1). Open bars: without compound, black bars: with indicated amount of compound. Cells were assayed for phagocytic activity as a measure of αSyn-mediated impairment of vesicular function. 4 μ beads were added for 90 minutes and a phagocytic index was calculated by microscopic visualization. Each sample was run in triplicate and experiments were run three independent times. The phagocytic indices for each individual experiment were averaged and statistical analyses run on the final averages from the three experiments. T-test analysis of the combined averages of the three experiments revealed a significant difference in phagocytosis between Tet-induced samples with and without ELN484228 (n = 3+/− s.e.m *p≤0.001 versus no compound Tet-induced sample). B. Microglia isolated from postnatal day 1 to 3 pups from hSNCAE46K transgenic (αSyn ) or non-transgenic littermates were incubated for 24 hours with 100 µM ELN484217 or ELN484228 followed by addition of 10 µm beads for 90 minutes. A phagocytic index was calculated by microscopic visualization (n = 3+/− s.e.m *p≤0.001). C. ELN484228 alleviates loss of dopaminergic neurons and neurite retraction induced by the A53T mutant of αSyn. Primary rat embryonic midbrain cultures were non-transduced (‘control’) or transduced with adenovirus encoding A53T αSyn, in the absence or presence of 10 µM ELN484228. The cells were then stained immunocytochemically for MAP2 and TH. Preferential dopaminergic cell death was assessed by evaluating the percentage of MAP2-positive cells that also stained positive for TH. The lengths of neurites staining positive for both MAP2 and TH were measured using the NIS-Elements software. Data are plotted as the mean ± s.e.m. n = 3 for neuron viability analysis; n = 160–206 for neurite length analysis. *p-value≤0.05, ***p-value≤0.001 versus aSyn A53T virus in the absence of compound; one-way ANOVA with Newman-Keuls post-test. D. ELN484228 reduces translocation of αSyn to the phagocytic cup. To assess αSyn translocation, H4 cells were treated with 100 µM ELN484228 and 1 µg/ml tetracycline for 24 hours; cells were then stimulated with 4 μ beads for 90 minutes. Samples were fixed and stained with 5C12 antibody to detect αSyn (red). Cells were counterstained with 488-phalloidin (green) and Hoechts (blue). A dotted circle indicates the position of the bead. E. ELN484228 reduces translocation of αSyn to synapses. Rat hippocampal neurons (∼21DIV) grown in serum-free conditions were treated for 24 hours with 1 µM ELN484228 or 0.01% DMSO vehicle. On the left side is a representative confocal microscopic image showing localization of αSyn (red) detected with 5C12 antibody, and localization of the presynaptic marker synaptophysin (green). Scale bar is 5 µm. Images were subjected to quantitative analysis and synaptic αSyn levels were determined as the amount of signal that colocalizes with the synaptic synaptophysin marker. Automated measurements were performed in Metamorph imaging analysis software to determine synaptic αSyn and synaptophysin levels by integrated intensity or pixel area, respectively. Values represent mean +/− SEM, n = 1000 terminals (αSyn) or 18 optical fields (synaptophysin) per condition, and derived from 2–3 independent cultures. Quantitation demonstrates that ELN484228 reduces the synaptic levels of αSyn in rat hippocampal neurons.
Figure 2 ELN484228 provides protection in cellular models of αSyn-mediated dysfunction. A. ELN484228 alleviates αSyn-mediated impairment of vesicular dynamics. H4 neuroglioma cells over-expressing αSyn from a tetracycline inducible promoter were cultured for 24 hours in the absence or presence of 1 µg/ml tetracycline to induce αSyn and ELN484228 or control compound ELN484217 (compound number 38 in table S4 in Supporting Information text file S1). Open bars: without compound, black bars: with indicated amount of compound. Cells were assayed for phagocytic activity as a measure of αSyn-mediated impairment of vesicular function. 4 μ beads were added for 90 minutes and a phagocytic index was calculated by microscopic visualization. Each sample was run in triplicate and experiments were run three independent times. The phagocytic indices for each individual experiment were averaged and statistical analyses run on the final averages from the three experiments. T-test analysis of the combined averages of the three experiments revealed a significant difference in phagocytosis between Tet-induced samples with and without ELN484228 (n = 3+/− s.e.m *p≤0.001 versus no compound Tet-induced sample). B. Microglia isolated from postnatal day 1 to 3 pups from hSNCAE46K transgenic (αSyn ) or non-transgenic littermates were incubated for 24 hours with 100 µM ELN484217 or ELN484228 followed by addition of 10 µm beads for 90 minutes. A phagocytic index was calculated by microscopic visualization (n = 3+/− s.e.m *p≤0.001). C. ELN484228 alleviates loss of dopaminergic neurons and neurite retraction induced by the A53T mutant of αSyn. Primary rat embryonic midbrain cultures were non-transduced (‘control’) or transduced with adenovirus encoding A53T αSyn, in the absence or presence of 10 µM ELN484228. The cells were then stained immunocytochemically for MAP2 and TH. Preferential dopaminergic cell death was assessed by evaluating the percentage of MAP2-positive cells that also stained positive for TH. The lengths of neurites staining positive for both MAP2 and TH were measured using the NIS-Elements software. Data are plotted as the mean ± s.e.m. n = 3 for neuron viability analysis; n = 160–206 for neurite length analysis. *p-value≤0.05, ***p-value≤0.001 versus aSyn A53T virus in the absence of compound; one-way ANOVA with Newman-Keuls post-test. D. ELN484228 reduces translocation of αSyn to the phagocytic cup. To assess αSyn translocation, H4 cells were treated with 100 µM ELN484228 and 1 µg/ml tetracycline for 24 hours; cells were then stimulated with 4 μ beads for 90 minutes. Samples were fixed and stained with 5C12 antibody to detect αSyn (red). Cells were counterstained with 488-phalloidin (green) and Hoechts (blue). A dotted circle indicates the position of the bead. E. ELN484228 reduces translocation of αSyn to synapses. Rat hippocampal neurons (∼21DIV) grown in serum-free conditions were treated for 24 hours with 1 µM ELN484228 or 0.01% DMSO vehicle. On the left side is a representative confocal microscopic image showing localization of αSyn (red) detected with 5C12 antibody, and localization of the presynaptic marker synaptophysin (green). Scale bar is 5 µm. Images were subjected to quantitative analysis and synaptic αSyn levels were determined as the amount of signal that colocalizes with the synaptic synaptophysin marker. Automated measurements were performed in Metamorph imaging analysis software to determine synaptic αSyn and synaptophysin levels by integrated intensity or pixel area, respectively. Values represent mean +/− SEM, n = 1000 terminals (αSyn) or 18 optical fields (synaptophysin) per condition, and derived from 2–3 independent cultures. Quantitation demonstrates that ELN484228 reduces the synaptic levels of αSyn in rat hippocampal neurons.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Tóth, G., Gardai, S. J., Zago, W., Bertoncini, C. W., Cremades, N., Roy, S. L., Tambe, M. A., Rochet, J.-C., Galvagnion, C., Skibinski, G., Finkbeiner, S., Bova, M., Regnstrom, K., Chiou, S.-S., Johnston, J., Callaway, K., Anderson, J. P., Jobling, M. F., Buell, A. K., Yednock, T. A., Knowles, T. P. J., Vendruscolo, M., Christodoulou, J., Dobson, C. M., Schenk, D., & McConlogue, L.
Affiliations
  • University of Cambridge (GB)
  • Elan Pharmaceuticals, Inc. (Ireland) (IE)
  • Purdue University West Lafayette (US)
  • Gladstone Institutes (US)
  • University College London (GB)
Corresponding author
  • Tóth, Gergely
  • Vendruscolo, Michele
  • Dobson, Christopher M.
  • Schenk, Dale
  • McConlogue, Lisa
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2014-02-14
Volume
9
Issue
2
Pages
e87133
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0087133
PMC
PMC3925190
OpenAlex
W2145653859
Cited by
151
References
70
Citations by year
2026: 5 · 2025: 9 · 2024: 7 · 2023: 11 · 2022: 9 · 2021: 12 · 2020: 16 · 2019: 7 · 2018: 19 · 2017: 16 · 2016: 18 · 2015: 12 · 2014: 10
FWCI
12.10
Type
journal article
Language
en
Update notices
correction (2014-05-27)
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
  • Americanae (AECID Library) (submittedVersion, cc-by-nc-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Greater South Information System
Funders
  • Wellcome Trust (097806)
  • University of Cambridge
  • Ministerio de Ciencia e Innovación
  • National Institutes of Health
  • Medical Research Council (MC_G1000734)
  • Biotechnology and Biological Sciences Research Council (BB/H003843/1)
  • National Institute of Neurological Disorders and Stroke (R01NS039074, R01NS083390)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
alpha-synuclein, Parkinson's disease, intrinsically disordered proteins, small molecule drug candidates, protein misfolding, vesicle trafficking, dopaminergic neurons, neurite retraction, microglia, synapses, drug repurposing
MeSH terms
Animals, Binding Sites, Humans, Models, Biological, Models, Molecular, Nerve Degeneration, Parkinson Disease, Phagocytes, Synapses, Mice, alpha-Synuclein, Small Molecule Libraries, Molecular Targeted Therapy, Dopaminergic Neurons, Intrinsically Disordered Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review